Daxor Corporation Announces Its 1998 Earnings.

NEW YORK--(BUSINESS WIRE)--March 26, 1999--

-0-

                           TWELVE MONTHS ENDED
                              December 1998            December 1997
Total Revenues                 $2,629,438                 $2,813,713
Net Income (loss)              $ (420,460)                $ (158,853)
Weighted Average Number
 Of shares outstanding          4,762,542                  4,696,876
Equivalent Share               $    (0.09)                $    (0.03)

The Daxor Corporation reported a loss of 9 cents per share for 1998. The company's revenues were negatively impacted by limited operations at its semen banking and blood banking facility. These facilities received new licenses in February 1998 and are expected to contribute to revenues in 1999. The Company had increased expenses related to the research and development of its (BVA-100) Blood Volume Analyzer, which is currently undergoing beta testing in a number of hospitals. The company expects the Blood Volume Analyzer to become the major source of revenue for the company. Measurement of blood volume is important in a wide range in a number of conditions ranging for transfusion therapy to hypertension and kidney disease. The company is currently developing a distribution network for the BVA-100. For additional information contact Fatima Baha or Dr. Joseph Feldschuh, President or company website Http://www.daxor.com.